Figure 2.
![Acquired resistance to naratuximab emtansine in DLBCL cells. (A-D) MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-dimethyltetrazolium bromide) assay (72 hours) in resistant and parental cells of SU-DHL-2 (A-B) and SU-DHL-4 (C-D) lines. Cell proliferation was evaluated in resistant and parental cells for naratuximab emtansine (Debio-1562) (left panels A and C) and its payload alone DM1 (right panels B and D). Bar plots correspond to IC50 values of resistant (red) and parental (blue) lines. (E-G) All data correspond to at least 3 independent experiments. Surface protein expression of CD37 by FACS in parental and naratuximab emtansine–resistant cell lines. ∗P < .05. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide.](https://ash.silverchair-cdn.com/ash/content_public/journal/bloodadvances/8/24/10.1182_bloodadvances.2023012291/1/blooda_adv-2023-012291-gr2.jpeg?Expires=1737914141&Signature=qn~TaiPrBKSJ5-PUCE3jdVVVar-DeaiQNgNdcit2s62Y0EcGgXyEHn15GV7fqBUqOvXsx29AxT-fDhdGHMQNFrUS03qpLLuBZDVXr2hSqyRKBhS8cX7mUDRyRsNK2exxnppdWy62JdkBinXijB4~OZs2QEqllg3DTtWo~zLqQMyfxdjaItSpyZRkGlPim8MpMxMbQL6MEEpI4O1FvLKYUR-UToIMMBiF4TVxOAQPDWQBZOjsN~n4mjaD9GZLgE8YKx1ELSjHHXR2iLzJ4LsnhPLyCC0OapauPaFzsJYrJ~D9urxHG48AvRk8WEPopMnts3hdGLgL1Uqjt8yWY5-esg__&Key-Pair-Id=APKAIE5G5CRDK6RD3PGA)
Acquired resistance to naratuximab emtansine in DLBCL cells. (A-D) MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-dimethyltetrazolium bromide) assay (72 hours) in resistant and parental cells of SU-DHL-2 (A-B) and SU-DHL-4 (C-D) lines. Cell proliferation was evaluated in resistant and parental cells for naratuximab emtansine (Debio-1562) (left panels A and C) and its payload alone DM1 (right panels B and D). Bar plots correspond to IC50 values of resistant (red) and parental (blue) lines. (E-G) All data correspond to at least 3 independent experiments. Surface protein expression of CD37 by FACS in parental and naratuximab emtansine–resistant cell lines. ∗P < .05. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide.
